×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
ContraFect submits IND for novel intravenous antibiotic
CIDRAP
Novel mechanism of action. In July 2020, ContraFect was awarded a grant by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical...
7 months ago
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
Yahoo Finance
CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trialYONKERS, N.Y., Oct. 16,...
6 months ago
Why Is ContraFect (CFRX) Stock Up 23% Today?
InvestorPlace
ContraFect stock is on the move Monday with heavy trading of CFRX as investors react to the latest clinical trial update from the FDA!
6 months ago
ContraFect halts phase 3 after antimicrobial fails futility test against MRSA
Fierce Biotech
ContraFect halts phase 3 after antimicrobial fails futility test against MRSA ... After keeping investors waiting for months, ContraFect has...
22 months ago
ContraFect begins Phase Ib/II clinical trial of exebacase
Clinical Trials Arena
ContraFect has commenced a Phase Ib/II clinical trial of exebacase in patients with chronic prosthetic joint infections (PJI) of the knee.
13 months ago
Contrafect Corporation CFRX is pretty much bust so why d the stock jump 154%?
Dhaka Tribune
Back in July last year the Contrafect trial was stopped by the Data Board (DSMB) on the basis that the results being shown were below the “...
12 months ago
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility ...
GlobeNewswire
The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the U.S. to assess the...
22 months ago
Pfizer Bought Penny Biotech Stock ContraFect Just Before It Doubled
Barron's
Pfizer took a $3 million stake in a biotech company called ContraFect about three weeks ago. Now it is worth more than $6 million.
52 months ago
'Uninterpretable' phase 3 results stymie ContraFect
Fierce Biotech
ContraFect's CEO has dubbed results from a phase 3 trial “uninterpretable," but the biotech is still clinging to hope that the drug can find...
16 months ago
Lysin therapy offers new hope for fighting drug-resistant bacteria - News
The Rockefeller University
Infections caused by MRSA bacteria (pictured) can lead to serious health complications. Lysins kill the microbes by destroying the...
63 months ago